Publication:
SEOM clinical guideline for the management of cutaneous melanoma (2020).

Loading...
Thumbnail Image

Date

2021-03-02

Authors

Majem, M
Manzano, J L
Marquez-Rodas, I
Mujika, K
Muñoz-Couselo, E
Pérez-Ruiz, E
de la Cruz-Merino, L
Espinosa, E
Gonzalez-Cao, M
Berrocal, A

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.

Description

MeSH Terms

Biopsy
Brain Neoplasms
Chemotherapy, Adjuvant
Follow-Up Studies
Humans
Immunotherapy
Lymph Node Excision
Medical Oncology
Melanoma
Molecular Targeted Therapy
Neoplasm Staging
Proto-Oncogene Proteins B-raf
Radiotherapy, Adjuvant
Skin Neoplasms
Societies, Medical
Spain

DeCS Terms

CIE Terms

Keywords

Adjuvant treatment metastatic treatment, Melanoma, Staging

Citation